Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Revisions Proposed to Re-pricing Rule, Adjustment Based on Average Overseas Prices
August 8, 2011
- US FDA Issues Refusal to File Letter for Eisai's Perampanel
August 8, 2011
- “Dispensing Point”System Contributing to Higher Average Price per Prescription: GROWELL
August 8, 2011
- Proemend, Teribone Recommended for Approval
August 8, 2011
- Application for Zonegran Monotherapy for Epilepsy Accepted in Europe: Eisai
August 8, 2011
- JAS to Assess Risk Factors Based on Absolute Risk in Its Revised GLs for Prevention of AD
August 8, 2011
- Recommendation for Approval Withheld for Avastin for Breast Cancer
August 8, 2011
- SUEVEY
August 8, 2011
- Pregabalin to Be Recommended as 1st-line Drug in New GLs for Peripheral Neuropathic Pain
August 8, 2011
- Takeda Resubmits NDA for DPP-4 Inhibitor in the US
August 8, 2011
- Takara Bio Announces TCR Gene Therapy Collaboration in China
August 8, 2011
- MIC to Test Electronic Prescribing System
August 8, 2011
- Korosho's New GLs Call For Use of IT to Distribute Safety Info.
August 8, 2011
- Takeda to Start Multinational PIII Trial for TAK-875 in FY2011
August 8, 2011
- R&D Spending Fell, Discontinued Clinical Trials Increased in 2010: Thomson Reuters
August 8, 2011
- Kyowa Kirin Files for PD Treatment KW-6500 in Japan
August 8, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
ページ
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…